Yorvipath is a drug owned by Ascendis Pharma Bone Diseases As. It is protected by 6 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 28, 2037. Details of Yorvipath's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11918628 | Controlled-release PTH compound |
Sep, 2037
(12 years from now) | Active |
| US11890326 | Controlled-release PTH compound |
Sep, 2037
(12 years from now) | Active |
| US8906847 | Prodrug comprising a drug linker conjugate |
Apr, 2031
(6 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11857603 | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(12 years from now) | Active |
| US11590207 | Dosage regimen for a controlled-release PTH compound |
Sep, 2037
(12 years from now) | Active |
| US11759504 | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(12 years from now) | Active |
FDA has granted several exclusivities to Yorvipath. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Yorvipath, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Yorvipath.
Exclusivity Information
Yorvipath holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Yorvipath's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
US patents provide insights into the exclusivity only within the United States, but Yorvipath is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Yorvipath's family patents as well as insights into ongoing legal events on those patents.
Yorvipath's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Yorvipath's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 28, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Yorvipath Generics:
There are no approved generic versions for Yorvipath as of now.
About Yorvipath
Yorvipath is a drug owned by Ascendis Pharma Bone Diseases As. Yorvipath uses Palopegteriparatide as an active ingredient. Yorvipath was launched by Ascendis Pharma Bone in 2024.
Approval Date:
Yorvipath was approved by FDA for market use on 09 August, 2024.
Active Ingredient:
Yorvipath uses Palopegteriparatide as the active ingredient. Check out other Drugs and Companies using Palopegteriparatide ingredient
Dosage:
Yorvipath is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) | SOLUTION | Prescription | SUBCUTANEOUS |
| EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) | SOLUTION | Prescription | SUBCUTANEOUS |
| EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) | SOLUTION | Prescription | SUBCUTANEOUS |